|
1）Kawa K, Okamura T, Yagi K, et al. Mosquito allergy and Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease. Blood. 2001; 98: 3173-4
|
|
|
|
2）Ohshima K, Kimura H, Yoshino T, et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lympho-proliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int. 2008; 58: 209-17
|
|
|
|
|
3）Quintanilla-Martinez L, Kimura H, Jaffe ES. EBV+ T-cell lymphoma of childhood. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of Tumours of Haemato-poietic and Lymphoid Tissues. 4th ed. Lyon: WHO Press; 2008. p. 278-80
|
|
|
|
|
|
4）Imashuku S, Hlbi S, Todo S. Hemophagocytic lymphohistiocytosis in infancy and childhood. Journal of Pediatrics. 1997; 130: 352-7
|
|
|
|
|
|
5）Okano M, Matsumoto S, Osato T, et al. Severe chronic active Epstein-Barr virus infection syndrome. Clin Microbiol Rev. 1991; 4: 129-35
|
|
|
|
|
|
6）Kikuta H, Taguchi Y, Tomizawa K, et al. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature. 1988; 333: 455-7
|
|
|
|
|
|
7）Kawa-Ha K, Ishihara S, Ninomiya T, et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest. 1989; 84: 51-5
|
|
|
|
|
|
8）Kawaguchi H, Miyashita T, Herbst H, et al. Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Invest. 1993; 92: 1444-50
|
|
|
|
|
|
9）Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001; 98: 280-6
|
|
|
|
|
|
10）Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood. 2001; 98: 1882-8
|
|
|
|
|
|
11）Iwatsuki K, Satoh M, Yamamoto T, et al. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol. 2006; 142: 587-95
|
|
|
|
|
|
12）Ishihara S, Okada S, Wakiguchi H, et al. Clonal lymphoproliferation following chronic active Epstein-Barr virus infection and hypersensitivity to mosquito bites. Am J Hematol. 1997; 54: 276-81
|
|
|
|
|
|
13）Takahashi E, Ohshima K, Kimura H, et al. Clinicopathological analysis of the age-related differences in patients with Epstein-Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders. Histopathology. 2011; 59: 660-71
|
|
|
|
|
|
14）Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003; 187: 527-33
|
|
|
|
|
|
15）Kawabe S, Ito Y, Gotoh K, et al. Application of flow cytometric in situ hybridization assay to Epstein-Barr virus (EBV)-associated T/NK lymphoproliferative diseases. Cancer Sci. 2012; 103: 1481-8
|
|
|
|
|
|
16）Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol. 2006; 16: 251-61
|
|
|
|
|
|
17）Ohga S, Ishimura M, Yoshimoto G, et al. Clonal origin of Epstein-Barr virus (EBV)-infected T/NK-cell subpopulations in EBV-positive T/NK-cell lymphoproliferative disorders of childhood. J Clin Virol. 2011; 51: 31-7
|
|
|
|
|
|
18）Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011; 117: 5835-49
|
|
|
|
|
|
19）Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012; 119: 673-86
|
|
|
|
|
|
20）Arai A, Imadome K, Watanabe Y, et al. Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis. Int J Hematol. 2011; 93: 602-9
|
|
|
|
|
|
21）Isobe Y, Aritaka N, Setoguchi Y, et al. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma. J Clin Pathol. 2012; 65: 278-82
|
|
|
|
|
|
22）Lay JD, Tsao CJ, Chen JY, et al. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest. 1997; 100: 1969-79
|
|
|
|
|
|
23）Kawada J, Kimura H, Shibata Y, et al. Evaluation of apoptosis in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Med Virol. 2006; 78: 400-7
|
|
|
|
|
|
24）Kimura H, Miyake K, Yamauchi Y, et al. Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by flow cytometric in situ hybridization in EBV-associated lympho-proliferative diseases. J Infect Dis. 2009; 200: 1078-87
|
|
|
|
|
|
25）Tanaka C, Hasegawa M, Fujimoto M, et al. Phenotypic analysis in a case of hydroa vaccini-forme-like eruptions associated with chronic active Epstein-Barr virus disease of gammadelta T cells. Br J Dermatol. 2012; 166: 216-8
|
|
|
|
|
|
26）Hirai Y, Yamamoto T, Kimura H, et al. Hydroa vacciniforme is associated with increased num-bers of Epstein-Barr virus-infected gammadelta T cells. J Invest Dermatol. 2012; 132: 1401-8
|
|
|
|
|
|
27）Tokura Y, Ishihara S, Ohshima K, et al. Severe mosquito bite hypersensitivity, natural killer cell leukaemia, latent or chronic active Epstein-Barr virus infection and hydroa vacciniforme-like eruption. Br J Dermatol. 1998; 138: 905-6
|
|
|
|
|
|
28）Asada H, Saito-Katsuragi M, Niizeki H, et al. Mosquito salivary gland extracts induce EBV-infected NK cell oncogenesis via CD4 T cells in patients with hypersensitivity to mosquito bites. J Invest Dermatol. 2005; 125: 956-61
|
|
|
|
|
|
29）Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007; 48: 124-31
|
|
|
|
|
|
30）Gotoh K, Ito Y, Shibata-Watanabe Y, et al. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis. 2008; 46: 1525-34
|
|
|
|
|
|
31）Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant. 2011; 46: 77-83
|
|
|
|
|
|
32）Wang Q, Liu H, Zhang X, et al. High doses of mothers lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood. Blood. 2010; 116: 5941-7
|
|
|
|
|
|
33）Cohen JI, Kimura H, Nakamura S, et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol. 2009; 20: 1472-82
|
|
|
|
|